A leading gastroenterologist has welcomed moves to relax PBS authority requirements for infliximab biosimilars for IBD patients. Following an application from MSD for the biosimilar Renflexis, the Pharmaceutical Benefits Advisory Committee has recommended streamlined authority access when patients have been stable on infliximab for two treatment cycles. Renflexis is a biosimilar to the infliximab originator product ...
PBS moves to ease access to biosimilars for IBD
By Tessa Hoffman
25 Jan 2018